## CLAIMS

We claim:

1. A method for treating TNF-mediated inflammatory diseases which comprises administering to a mammal in need thereof a therapeutically effective amount of a TNF antagonist.

2. A method according to claim 1, wherein the TNF-mediated inflammatory disease is arthritis.

3. A method according to claim 2, wherein the mammal is a human.

4. A method according to claim 3, wherein the TNF antagonist is soluble human TNFR.

5. A method according to claim 4, wherein the soluble human TNFR is selected from the group consisting of soluble human Type I TNFR and soluble human Type II TNFR.

6. A method according to claim 4, wherein the soluble human TNFR is fused to the Fc region of a human immunoglobulin molecule.

7. A method according to claim 2, wherein TNFR is administered in combination with IL-1R.

8. A method for treating arthritis in a mammal, comprising the step of administering to a mammal having arthritis an amount of soluble human TNFR ranging from about 0.1 mg/kg/week to about 100 mg/kg/week.

9. A method according to claim 8, wherein the amount of soluble human TNFR ranges from about 0.5 mg/kg/week to about 50 mg/kg/week.